Orexigen Therapeutics, Inc.·4

Oct 17, 7:16 PM ET

NARACHI MICHAEL 4

4 · Orexigen Therapeutics, Inc. · Filed Oct 17, 2017

Insider Transaction Report

Form 4
Period: 2017-10-13
NARACHI MICHAEL
DirectorPresident and CEO
Transactions
  • Award

    Restricted Stock Unit (RSU)

    2017-10-13+252,000252,000 total
    Common Stock (252,000 underlying)
Footnotes (3)
  • [F1]Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
  • [F2]Reflects an award of restricted stock units ("RSUs"), each representing a contingent right to receive a share of the issuer's common stock upon settlement.
  • [F3]Twenty-five percent (25%) of the RSUs will vest on each of the first four (4) anniversaries of February 3, 2018 (each, a "Vesting Date"), subject to the reporting person's continued eigibility on each applicable Vesting Date.

Documents

2 files
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION

  • EX-24.4_748541

    POA DOCUMENT